Line of business: BlueAlliance (Commercial) & BlueAlliance Care+ (Medicaid)
The percentage of new substance use disorder (SUD) episodes resulting in treatment initiation and engagement.
Two rates are reported:
Description | Prescription |
Aldehyde dehydrogenase inhibitor | Disulfiram (oral) |
Antagonist | Naltrexone (oral and injectable) |
Other | Acamprosate (oral; delayed-release tablet) |
Description | Prescription |
Antagonist | Naltrexone (oral) |
Antagonist | Naltrexone (injectable) |
Partial agonist | Buprenorphine (sublingual tablet) |
Partial agonist | Buprenorphine (injection) |
Partial agonist | Buprenorphine (implant) |
Partial agonist | Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) |
Note:
Methadone is not included on the medication list. Methadone for opioid use disorder is only administered or dispensed by federally certified opioid treatment programs and is not billed through pharmacy claims.
The analysis of any medical coding question related to a measure is dependent on the measure’s technical specifications including the factual situations present related to the member, the practice, the professionals, and the medical services provided.
Should you have specific coding or other questions related to the measure, please send your questions to BlueAlliance@bcbsnd.com.
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).